$CARM
Carisma Therapeutics Inc

2015 Q2 Form 10-Q Financial Statement

#000119312515161906 Filed on April 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $114.0K $244.0K $568.0K
YoY Change -85.02% -57.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.250M $2.600M $1.940M
YoY Change 9.76% 34.02% 106.38%
% of Gross Profit
Research & Development $6.269M $5.238M $5.819M
YoY Change -7.18% -9.98% 29.43%
% of Gross Profit
Depreciation & Amortization $90.00K $100.0K $100.0K
YoY Change -18.18% 0.0% -16.67%
% of Gross Profit
Operating Expenses $8.516M $7.841M $7.757M
YoY Change -3.29% 1.08% 42.72%
Operating Profit -$8.402M -$7.597M -$7.189M
YoY Change 4.44% 5.68% 32.27%
Interest Expense -$330.0K -$235.0K -$84.00K
YoY Change 317.72% 179.76% 6.33%
% of Operating Profit
Other Income/Expense, Net $1.496M $1.073M -$33.00K
YoY Change -2068.42% -3351.52% -57.14%
Pretax Income -$6.910M -$6.520M -$7.220M
YoY Change -14.9% -9.7% 31.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.906M -$6.524M -$7.222M
YoY Change -14.96% -9.66% 31.02%
Net Earnings / Revenue -6057.89% -2673.77% -1271.48%
Basic Earnings Per Share
Diluted Earnings Per Share -$362.0K -$362.8K -$749.0K
COMMON SHARES
Basic Shares Outstanding 19.37M shares 18.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.50M $45.50M $54.00M
YoY Change 18.89% -15.74%
Cash & Equivalents $53.49M $45.55M $53.96M
Short-Term Investments
Other Short-Term Assets $900.0K $600.0K $400.0K
YoY Change -10.0% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $54.43M $46.14M $54.41M
YoY Change 18.25% -15.2%
LONG-TERM ASSETS
Property, Plant & Equipment $580.0K $422.0K $708.0K
YoY Change -14.96% -40.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.00K $18.00K $18.00K
YoY Change 6.67% 0.0%
Total Long-Term Assets $690.0K $440.0K $820.0K
YoY Change -12.77% -46.34%
TOTAL ASSETS
Total Short-Term Assets $54.43M $46.14M $54.41M
Total Long-Term Assets $690.0K $440.0K $820.0K
Total Assets $55.12M $46.58M $55.23M
YoY Change 17.72% -15.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.880M $2.043M $3.070M
YoY Change -27.75% -33.45%
Accrued Expenses $618.0K $1.327M $457.0K
YoY Change -45.79% 190.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.500M $1.000M $1.600M
YoY Change 56.25% -37.5%
Total Short-Term Liabilities $5.472M $4.642M $6.303M
YoY Change -9.21% -26.35%
LONG-TERM LIABILITIES
Long-Term Debt $12.20M $9.000M $2.500M
YoY Change 480.95% 260.0%
Other Long-Term Liabilities $164.0K $65.00K $200.0K
YoY Change 64.0% -67.5%
Total Long-Term Liabilities $164.0K $65.00K $2.700M
YoY Change -92.55% -97.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.472M $4.642M $6.303M
Total Long-Term Liabilities $164.0K $65.00K $2.700M
Total Liabilities $5.636M $4.707M $9.000M
YoY Change -31.27% -47.7%
SHAREHOLDERS EQUITY
Retained Earnings -$105.2M -$98.27M -$64.82M
YoY Change 44.21% 51.62%
Common Stock $19.00K $18.00K $16.00K
YoY Change 18.75% 12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.22M $30.97M $46.23M
YoY Change
Total Liabilities & Shareholders Equity $55.12M $46.58M $55.23M
YoY Change 17.72% -15.66%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$6.906M -$6.524M -$7.222M
YoY Change -14.96% -9.66% 31.02%
Depreciation, Depletion And Amortization $90.00K $100.0K $100.0K
YoY Change -18.18% 0.0% -16.67%
Cash From Operating Activities -$9.030M -$8.480M -$5.030M
YoY Change 6.86% 68.59% -7.2%
INVESTING ACTIVITIES
Capital Expenditures -$260.0K $32.00K $50.00K
YoY Change 225.0% -36.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$260.0K -$30.00K -$50.00K
YoY Change 225.0% -40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$46.00K $51.51M
YoY Change -100.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.23M 0.000 51.11M
YoY Change -4302.44% -100.0% 1615.1%
NET CHANGE
Cash From Operating Activities -9.030M -8.480M -5.030M
Cash From Investing Activities -260.0K -30.00K -50.00K
Cash From Financing Activities 17.23M 0.000 51.11M
Net Change In Cash 7.940M -8.510M 46.03M
YoY Change -188.81% -118.49% -1986.48%
FREE CASH FLOW
Cash From Operating Activities -$9.030M -$8.480M -$5.030M
Capital Expenditures -$260.0K $32.00K $50.00K
Free Cash Flow -$8.770M -$8.512M -$5.080M
YoY Change 4.78% 67.56% -6.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19371411 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53964000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18015423 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18015423 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1593293 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.74
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
645757 shares
CY2015Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8990000
CY2015Q1 us-gaap Interest Payable Current
InterestPayableCurrent
81000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.91
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.19
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1933158 shares
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4642000
CY2015Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1915000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
18000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2043000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98274000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1327000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
30966000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
65000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46578000
CY2015Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1915000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129222000
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
192000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
262000
CY2015Q1 us-gaap Notes Payable Current
NotesPayableCurrent
1010000
CY2015Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1915000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
384000
CY2015Q1 us-gaap Construction Payable Current
ConstructionPayableCurrent
588000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45549000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1700000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
94000
CY2015Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
45549000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
495000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4600000
CY2015Q1 us-gaap Assets
Assets
46578000
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45549000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5900000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
46138000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1438528 shares
CY2015Q1 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7942000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17933260 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17933260 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.93
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5202000
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3219000
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9749000
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
84000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91750000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1987000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36826000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55000000
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
3219000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
128558000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
195000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
506000
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
251000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
3219000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
874000
CY2014Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
834000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54059000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54059000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
342000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2014Q4 us-gaap Assets
Assets
55000000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54059000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
54401000
CY2015Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y8M1D
CY2015Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.6219 pure
CY2015Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2015Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0089 pure
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.82
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1618108 shares
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
186000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7189000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
CY2014Q1 us-gaap Revenues
Revenues
568000
CY2014Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
416000
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-84000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
CY2014Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y11M1D
CY2014Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.5679 pure
CY2014Q4 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0110 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5034000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9635000 shares
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M10D
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7741000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7222000
CY2014Q1 us-gaap Interest Paid
InterestPaid
64000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-113000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
7757000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5819000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46022000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-215000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
101000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
51106000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51507000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-50000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
8000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1938000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1885000
CY2014Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
519000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
636000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
120000
CY2014Q1 ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
56678000
CY2014Q1 ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
247000
CY2015Q1 us-gaap Collaborative Arrangement Rights And Obligations
CollaborativeArrangementRightsAndObligations
The Company has granted ThromboGenics an exclusive, sublicenseable, royalty-bearing license under the Company's rights in these patent rights and know-how, as well as under any other patent rights and know-how that the Company controls during the research term that are necessary for ThromboGenics to perform its obligations to research, develop, manufacture and commercialize collaboration products.
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y5M12D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
566556 shares
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2015Q1 dei Trading Symbol
TradingSymbol
EBIO
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y11D
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8478000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
17555 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17971000 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M7D
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.83
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M6D
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.78
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2931033 shares
CY2015Q1 us-gaap Collaborative Arrangement Nature And Purpose
CollaborativeArrangementNatureAndPurpose
Under this agreement, the Company and ThromboGenics are collaborating to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease.
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
54371 shares
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
215000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7597000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1304000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-598000
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-235000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1073000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1308000
CY2015Q1 us-gaap Revenues
Revenues
244000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6524000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6524000
CY2015Q1 us-gaap Interest Paid
InterestPaid
175000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-244000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
7841000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5238000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8510000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-46000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-32000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46000
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
2000
CY2015Q1 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
0
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2603000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-415000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
664000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
584000
CY2015Q1 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000
CY2015Q1 ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
CY2015Q1 ebio Change In Fair Value Of Preferred Stock Warrants
ChangeInFairValueOfPreferredStockWarrants
1304000
CY2015Q1 ebio Collaborative Arrangement Date Of Agreement
CollaborativeArrangementDateOfAgreement
2013-05-28

Files In Submission

Name View Source Status
0001193125-15-161906-index-headers.html Edgar Link pending
0001193125-15-161906-index.html Edgar Link pending
0001193125-15-161906.txt Edgar Link pending
0001193125-15-161906-xbrl.zip Edgar Link pending
d914010d10q.htm Edgar Link pending
d914010dex311.htm Edgar Link pending
d914010dex312.htm Edgar Link pending
d914010dex321.htm Edgar Link pending
ebio-20150331.xml Edgar Link completed
ebio-20150331.xsd Edgar Link pending
ebio-20150331_cal.xml Edgar Link unprocessable
ebio-20150331_def.xml Edgar Link unprocessable
ebio-20150331_lab.xml Edgar Link unprocessable
ebio-20150331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending